Causal Inference Book
hsph.harvard.edu
hsph.harvard.edu
I'm surprised that causal discovery doesn't get more play. Aside from the direct applications to scientific research, causality is a strong consistency hint for assessing models/features learned from data.
[1] https://news.ycombinator.com/item?id=8776582
[2] https://opensource.googleblog.com/2014/09/causalimpact-new-o...
Part of me wants to dive into this causality modeling, because it seems up my alley, but I'm very sceptical of it showing anything definitive. I do observational research, but short of a priori randomization, I'm sceptical of any claims to causality. Even then, with experiments, I'm deeply sceptical unless something has been replicated across various secondary conditions by multiple distinct groups.
Modern causality theory and modeling has definitely raised the bar in terms of what we say about data, and I love it, but sometimes I wonder if causality is a red herring. Even with hard experimental evidence, I'm tempted to not interpret it beyond "when someone does X, this tends to happen."
It's what drove me back to hard interventional experiments and eventually to adaptive clinical trial design.
(Asterisk): ok more like Pearl started it and Robins made it more practical with doubly robust designs etc. I still find most of the mechanics rather shady.
Interesting, can you expand on this? I have no experience with causal inference and would like to learn more. Thanks!
I'm wondering if their methodology is reasonable?
From the abstract: “Millions of times each year, judges must decide where defendants will await trial—at home or in jail. By law, this decision hinges on the judge’s prediction of what the defendant would do if released. … Yet comparing the algorithm to the judge proves complicated. … We only observe crime outcomes for released defendants, not for those judges detained. This makes it hard to evaluate counterfactual decision rules based on algorithmic predictions. … We deal with these problems using different econometric strategies, such as quasi-random assignment of cases to judges. … A policy simulation shows crime can be reduced by up to 24.8% with no change in jailing rates, or jail populations can be reduced by 42.0% with no increase in crime rates. Moreover, we see reductions in all categories of crime, including violent ones. Importantly, such gains can be had while also significantly reducing the percentage of African-Americans and Hispanics in jail. … While machine learning can be valuable, realizing this value requires integrating these tools into an economic framework: being clear about the link between predictions and decisions; specifying the scope of payoff functions; and constructing unbiased decision counterfactuals.”
I'm no economist, though. Perhaps this is novel at NBER. It's just odd to see someone acting like using an ensemble to enable data-driven model selection is something new.
nb. I didn't read the entire 76-page paper (partly because it's obscenely verbose). A quick skim and here are my from-the-hip remarks. If they suck, I'll refund every cent you paid me ;-)
“Outcome regression and various versions of propensity score analyses are the most commonly used parametric methods for causal inference. You may rightly wonder why it took us so long to include a chapter that discusses these methods. So far we have described IP weighting, the g-formula, and g-estimation–the g-methods. Presenting the most commonly used methods after the least commonly used ones seems an odd choice on our part. Why didn’t we start with the simpler and widely used methods based on outcome regression and propensity scores? Because these methods do not work in general. More precisely, the simpler outcome regression and propensity score methods–as described in a zillion publications that this chapter cannot possibly summarize–work fine in simpler settings, but these methods are not designed to handle the complexities associated with causal inference for time-varying treatments.”
Does anyone in this area have a succinct way to explain how counterfactual data can be inferred by these techniques - and how traditional statistics practice is not able to perform this inference?
I wish abbreviations like inverse probability weighting and marginal structural models were expanded in the second book. It's annoying to have to look up "IP weighting" only to discover "oh, it's IPW, god damn you [authors] to hell".
MSMs are interesting. Now I remember why Robins' name stuck in my head. The book shows all the math explicitly, which is nice, and it delves into causal inference for time-to-event data, which is also nice.
Now I'm curious whether they look at piecewise constant survival models for time-varying coefficients. It's mentioned, but I didn't read enough to see if it's treated in detail. If it is, everyone who does A/B testing should read the book, because this is one of those "little details" from biostatistics that becomes super important at big retailers (like, say, Amazon, where the principal economist at the time pointed it out to me).
Regarding the automatic analysis, Automatic Statistician (Tenenbaum & Ghahramani et al.), which is supposed to automate / assist the exploratory analysis, comes to mind. Not sure if it'd be fair but I tend to lump some of the probabilistic programming - such as BayesDB - platforms into the same bucket. While these are exploratory tools, they are ideally (pragmatically) meant to help identify associations and context whereby correlation is highly suggestive of causation.
Another area of interest: one of the comments below mentioned adaptive clinical trial design. I know that Bayesian trials are intensively implemented in some cancer research centers such as MD Anderson (off-topic: curious to what extent IBM Watson was used as part of this protocol). I would love to know whether adaptive trials are increasingly popular or widely used in pharma industry.